• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Biogen Idec (NQ:BIIB)

    192.18 +3.77 (+2.00%)
    Streaming Delayed Price Updated: 11:15 AM EDT, Mar 11, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Biogen Idec

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Announces Board Chair Transition
    Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair 
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Completes Acquisition of Alcyone Therapeutics
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
    LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive,... 
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.